RE:RE:RE:RE:RE:RE:RE:RE:There's a bunch of drinks already on the marketHere you go man..They have translators on the internet now...
HC Biomed: Did you pay attention?
Facebook "Like" dummy "Tweet this" dummy "Google + 1" dummy settings
18.08.18 13:59
Share News
In our new analysis, we take a closer look at THC Biomed, a company in the pharmaceuticals market. The THC Biomed share was quoted at 0.64 on 17.08.2018.
Based on a total of 4 evaluation criteria, we have developed an assessment of the current level for THC Biomed. At each level, the company receives the "buy", "hold" or "sell" rating. This results in a final weighting of the overall grade.
1. Investors: THC Biomed's discussions on social media platforms send out a clear message about the valuation and sentiment surrounding the title. At present, the comments and opinions in the last two weeks show a generally positive opinion. In contrast, in the past few days, negative topics around value were mostly addressed. Thus, our editors come to the conclusion, the company is classified as a "Hold". In summary, the editorial board therefore believes that THC Biomed's stock is appropriately valued in terms of investor sentiment as "hold".
2. Sentiment and Buzz: There has been an increase in negative comments on THC Biomed in social media over the last few weeks. The sentiment barometer of the market participants pointed in the red area. The stock therefore receives a "sell" rating from the editors. The intensity, or rather simply, the frequency of contributions to a stock provides indications of whether the company currently has much or little focus on investors. THC Biomed has been discussed much more than normal, and there is increasing attention. This leads to a "buy" rating. Overall, the stock gets a "sell" rating.
3. Technical Analysis: A consideration of the technical performance of a stock using the moving average can be used to determine the current trend of the security. Let's take a look at the moving average closing price of the THC Biomed share over the past 200 trading days. This value is currently 0.99. Thus, the last closing price (0.64) is significantly lower (difference -35.35 percent). We therefore rate the share as a "sell" on this basis. What is this calculation when you determine the moving average based on the last 50 trading days? For this (0.81) the last closing price is also below the moving average (-20.99 percent deviation). The THC Biomed share is therefore also considered on this shorter-term basis with a "sell" rating. The THC Biomed share will therefore be given a "sell" rating in total for the simple chart technique.